Cell Line Origin
Human caucasian chronic myelogenous leukemia (drug resistant)
Cell Line Description
The drug resistant cell line K562 AZQ has been developed from the parent K562 cell line (Sigma Catalogue number. 89121407) by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone). The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.
Application
Drug-resistance studies
Culture Medium
RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage.
Subculture Routine
Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Disclaimer
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.
biological source: human blood. growth mode: Suspension. karyotype: Not specified. morphology: Lymphoblastoid. products: Not specified. receptors: Not specified. technique(s): cell culture | mammalian: suitable. relevant disease(s): cancer. shipped in: dry ice. storage temp.: −. 196°C.- UPC:
- 51284717
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 93112521-1VL
